Exposure‐response relationships of etrolizumab in patients with moderately‐to‐severely active ulcerative colitis

Etrolizumab is an IgG1‐humanized monoclonal anti‐β7 integrin antibody. Phase III trials with induction and/or maintenance phases were conducted in patients with moderately‐to‐severely active ulcerative colitis (UC) who were either previously treated with tumor necrosis factor (TNF) inhibitors (HICKO...

Descripción completa

Detalles Bibliográficos
Autores principales: Kassir, Nastya, Zhu, Rui, Moein, Anita, Langenhorst, Jurgen, Ribbing, Jakob, Zhang, Rong, Tang, Meina T., Oh, Young S., Zhang, Wenhui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469693/
https://www.ncbi.nlm.nih.gov/pubmed/35789549
http://dx.doi.org/10.1002/psp4.12840

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9469693/
https://www.ncbi.nlm.nih.gov/pubmed/35789549
http://dx.doi.org/10.1002/psp4.12840

Ejemplares similares